| Translated title of the contribution | Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. |
|---|---|
| Original language | Undefined/Unknown |
| Pages (from-to) | 646-655 |
| Number of pages | 10 |
| Journal | The Lancet |
| Volume | 372 |
| Issue number | 9639 |
| Publication status | Published - 2008 |
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
J.-M. Molina, J. Andrade-Villanueva, I.M. Hoepelman, Study Team Castle
Research output: Contribution to journal › Article › Academic › peer-review